Welcome to the July 2018 edition of our Updates on Myeloproliferative Neoplasms (MPNs) newsletter. This month, we highlight MPN research from the recent 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, including trials investigating the role of ruxolitinib and JAK1/2 inhibitor therapies in relation to allogeneic stem cell transplant, and an ongoing study of luspatercept for the treatment of myelofibrosis-induced anemia.
We also explore exciting new data on the relationship between the SOCS1 and JAK proteins and what this means for future MPN therapies. Additionally, we feature an article that proposes an increased risk of aggressive B-cell lymphoma for some patients with myelofibrosis.
If you’re looking to learn more, we have a plethora of other MPN resources to boost your knowledge:
I hope you enjoy this month’s newsletter and the enduring MPN resources we’ve created to ensure you take away valuable insights for your practice.
Please feel free to share this newsletter with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at email@example.com at any time.
Lindsey Lyle, MS, PA-C
University of Colorado, Anschutz Medical Campus